Drug Information

Drug General Information
Drug ID
D0W8BP
Former ID
DNC008895
Drug Name
C[Cpa19-Lys26][Gly8]GLP-1(7-37)-NH2
Indication Discovery agent Investigative [529424]
Structure
Download
2D MOL

3D MOL
Formula
C151H225N41O46
Canonical SMILES
CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC<br />(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCCN)C(=O)NCC(=O)NC(CCCNC(=<br />N)N)C(=O)NCC(=O)N)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O<br />)NC(=O)C4CCCCNC(=O)C5=CC=C(CC(C(=O)NC(C(=O)NC(C(=O)NCC(<br />=O)NC(C(=O)NC(C(=O)NC(C(=O)N4)C)C)CCC(=O)N)CCC(=O)O)CC(<br />C)C)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O<br />)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(<br />C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC7=CNC=N7<br />)N)C=C5
InChI
1S/C151H225N41O46/c1-16-77(10)121(148(236)170-80(13)126(214)178-104(59-87-62-161-91-35-24-23-34-89(87)91)138(226)180-100(55-74(4)5)139(227)189-119(75(6)7)146(234)177-93(36-25-27-51-152)130(218)164-66-112(201)171-92(38-29-53-160-151(156)157)129(217)162-64-110(155)199)191-140(228)102(56-83-30-19-17-20-31-83)181-135(223)98(46-50-117(208)209)176-134(222)94-37-26-28-52-159-127(215)86-41-39-85(40-42-86)58-101(137(225)179-99(54-73(2)3)136(224)175-96(45-49-116(206)207)132(220)165-67-113(202)173-97(43-47-109(154)198)133(221)169-78(11)124(212)168-79(12)125(213)174-94)182-143(231)106(69-193)185-145(233)108(71-195)186-147(235)120(76(8)9)190-142(230)105(61-118(210)211)183-144(232)107(70-194)187-150(238)123(82(15)197)192-141(229)103(57-84-32-21-18-22-33-84)184-149(237)122(81(14)196)188-114(203)68-166-131(219)95(44-48-115(204)205)172-111(200)65-163-128(216)90(153)60-88-63-158-72-167-88/h17-24,30-35,39-42,62-63,72-82,90,92-108,119-123,161,193-197H,16,25-29,36-38,43-61,64-71,152-153H2,1-15H3,(H2,154,198)(H2,155,199)(H,158,167)(H,159,215)(H,162,217)(H,163,216)(H,164,218)(H,165,220)(H,166,219)(H,168,212)(H,169,221)(H,170,236)(H,171,201)(H,172,200)(H,173,202)(H,174,213)(H,175,224)(H,176,222)(H,177,234)(H,178,214)(H,179,225)(H,180,226)(H,181,223)(H,182,231)(H,183,232)(H,184,237)(H,185,233)(H,186,235)(H,187,238)(H,188,203)(H,189,227)(H,190,230)(H,191,228)(H,192,229)(H,204,205)(H,206,207)(H,208,209)(H,210,211)(H4,156,157,160)/t77-,78-,79-,80-,81+,82+,90-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,119-,120-,121-,122-,123-/m0/s1
InChIKey
NBZJWICSDFBTTN-RHBBJNDVSA-N
PubChem Compound ID
44577348
Target and Pathway
Target(s) Glucagon-like peptide 1 receptor Target Info Inhibitor [529424]
KEGG Pathway cAMP signaling pathway
Neuroactive ligand-receptor interaction
Insulin secretion
Reactome Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
G alpha (s) signalling events
Glucagon-type ligand receptors
WikiPathways GPCRs, Class B Secretin-like
Integration of energy metabolism
GPCR ligand binding
GPCR downstream signaling
References
Ref 529424J Med Chem. 2008 May 8;51(9):2758-65. Epub 2008 Apr 15.Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo activity.
Ref 529424J Med Chem. 2008 May 8;51(9):2758-65. Epub 2008 Apr 15.Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo activity.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.